首次监测性结肠镜检查后结直肠癌发病率及持续监测的必要性:一项回顾性队列分析
该回顾性队列分析纳入17家英国医院10508例息肉切除后接受≥1次监测性结肠镜检查的患者,按2020年英国指南基线及SC1风险分层。SC1后中位随访8.0年诊断151例结直肠癌,LR-LR组发病率低于一般人群,HR-HR组高于一般人群,HR-HR组在SC2后不再高于一般人群。结论为基线和SC1均为高风险者需SC2,SC1低风险者不需后续监测。
要点
- SC1后中位随访8.0年,LR-LR组结直肠癌发病率低于一般人群(SIR 0.48)。
- HR-HR组SC1后结直肠癌发病率高于一般人群(SIR 2.84),SC2后不再高于一般人群(SIR 1.86)。
- SC1低风险者无论基线风险如何均不需进一步监测,HR-HR组需SC2。
核心结论
- 基线和SC1均为高风险的患者需要SC2,而SC1为低风险的患者不需要,无论其基线结果如何。
研究设计与样本
- 回顾性分析17家英国医院接受结肠镜检查及息肉切除术、且≥1次监测性结肠镜检查的患者,多数从2000年至2010年,癌症和死亡数据收集至2017年。
- 分析纳入10508例患者:LR-LR=6587例(63%),HR-LR=3272例(31%),LR-HR=248例(2%),HR-HR=401例(4%)。
- 采用2020年英国息肉切除后监测指南的风险定义分组,比较SC1后及SC2后结直肠癌发病率与一般人群发病率(标准化发病率比SIR)。
主要发现
- SC1后中位随访8.0年,诊断151例结直肠癌。
- 与一般人群相比,SC1后结直肠癌发病率在LR-LR组较低(SIR 0.48,95%CI 0.34至0.67),HR-LR组(SIR 1.17,95%CI 0.85至1.58)或LR-HR组(SIR 2.51,95%CI 0.81至5.85)无显著差异,HR-HR组较高(SIR 2.84,95%CI 1.30至5.39)。
- SC2后,HR-HR组结直肠癌发病率不再高于一般人群(SIR 1.86,95%CI 0.89至3.42)。
关键数值与推荐
- LR-LR组SC1后结直肠癌发病率SIR 0.48(95%CI 0.34至0.67),低于一般人群。
- HR-LR组SC1后SIR 1.17(95%CI 0.85至1.58),与一般人群无显著差异。
- LR-HR组SC1后SIR 2.51(95%CI 0.81至5.85),与一般人群无显著差异。
- HR-HR组SC1后SIR 2.84(95%CI 1.30至5.39),高于一般人群;SC2后SIR 1.86(95%CI 0.89至3.42),不再高于一般人群。
临床怎么用
- 对于基线和SC1均为高风险(HR-HR)的患者,需进行第二次监测性结肠镜检查(SC2)。
- 对于SC1为低风险的患者,无论基线风险如何,不需要进一步监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommendations for the first postpolypectomy surveillance colonoscopy (SC1), based on stratifying postpolypectomy colorectal cancer (CRC) risk, are well established. Limited data inform recommendations for surveillance beyond SC1. OBJECTIVE: We investigated which patient groups need surveillance beyond SC1. DESIGN: Retrospective analysis of patients who underwent colonoscopy with polypectomy at 17 UK hospitals, mostly from 2000 to 2010, and had ≥1 surveillance colonoscopies. Cancer and death data were collected through 2017. We examined patients in groups defined by risk at baseline and SC1, applying risk definitions from the 2020 UK postpolypectomy surveillance guidelines: 'low risk, low risk' (LR-LR), 'high risk, low risk' (HR-LR), 'low risk, high risk' (LR-HR) and 'high risk, high risk' (HR-HR). We examined CRC incidence after SC1, censoring at any second surveillance colonoscopy (SC2), and after SC2 through end of follow-up. We compared incidence with general population incidence using standardised incidence ratios (SIRs). RESULTS: Analyses included 10 508 patients: LR-LR=6587 (63%), HR-LR=3272 (31%), LR-HR=248 (2%) and HR-HR=401 (4%). Median follow-up from SC1 was 8.0 years and 151 CRCs were diagnosed. Compared with the general population, CRC incidence after SC1 was lower in the LR-LR group (SIR 0.48, 95% CI 0.34 to 0.67), non-significantly different in the HR-LR (SIR 1.17, 0.85 to 1.58) or LR-HR (SIR 2.51, 0.81 to 5.85) groups, but higher in the HR-HR group (SIR 2.84, 1.30 to 5.39). After SC2, CRC incidence in the HR-HR group was no longer higher than in the general population (SIR 1.86, 0.89 to 3.42). CONCLUSION: Patients with high-risk findings at both baseline and SC1 needed an SC2, while those with low-risk findings at SC1 did not, regardless of their baseline findings.
引用
- Robbins EC, Wooldrage K, Rutter MD, et al. Colorectal cancer incidence after the first surveillance colonoscopy and the need for ongoing surveillance: a retrospective, cohort analysis. Gut. 2025. PMID: 40187891. doi:10.1136/gutjnl-2024-334242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。